PMID- 21563859
OWN - NLM
STAT- MEDLINE
DCOM- 20110930
LR  - 20221207
IS  - 1744-7682 (Electronic)
IS  - 1471-2598 (Linking)
VI  - 11
IP  - 7
DP  - 2011 Jul
TI  - Liraglutide for type 2 diabetes mellitus.
PG  - 951-9
LID - 10.1517/14712598.2011.583641 [doi]
AB  - INTRODUCTION: Prevalence of type 2 diabetes mellitus (T2DM) is increasing. 
      Management of this condition and minimizing the cardiovascular risks associated 
      with it poses a significant burden on healthcare resources across the world. 
      Currently available therapeutic agents are effective in glycemic management; 
      however, the majority of these are associated with undesirable effects such as 
      hypoglycemia and weight gain. Incretin-based therapies have been introduced over 
      the last few years and are associated with less risk of hypoglycemia and weight 
      gain. AREAS COVERED: This review includes current challenges in the management of 
      T2DM, and an overview of glucagon-like peptide-1 (GLP-1)-based therapies, in 
      particular the results of Phase III clinical studies of recently approved 
      liraglutide. Apart from glycemic control, multifactorial interventions are needed 
      to minimize the cardiovascular risks associated with T2DM. Liraglutide is 
      effective in improving glycemic control measured by HbA1c and it is also shown to 
      improve weight. Recently, the National Institute of Health and Clinical 
      Excellence in the UK has approved liraglutide 1.2 mg dose in dual and triple 
      therapy for T2DM. EXPERT OPINION: Liraglutide, a once-daily GLP-1 analog, has a 
      definite role in selected patients with T2DM and the long-term cardiovascular 
      safety is currently being ascertained in ongoing trials.
FAU - Kela, Ram
AU  - Kela R
AD  - University Hospitals of Leicester NHS Trust, Leicester, LE1 5WW, UK.
FAU - Khunti, Kamlesh
AU  - Khunti K
FAU - Davies, Melanie J
AU  - Davies MJ
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
DEP - 20110512
PL  - England
TA  - Expert Opin Biol Ther
JT  - Expert opinion on biological therapy
JID - 101125414
RN  - 0 (Biomarkers)
RN  - 0 (Blood Glucose)
RN  - 0 (Glycated Hemoglobin A)
RN  - 0 (Hypoglycemic Agents)
RN  - 0 (hemoglobin A1c protein, human)
RN  - 839I73S42A (Liraglutide)
RN  - 89750-14-1 (Glucagon-Like Peptide 1)
SB  - IM
MH  - Biomarkers/blood
MH  - Blood Glucose/drug effects
MH  - Diabetes Mellitus, Type 2/blood/*drug therapy
MH  - Drug Administration Schedule
MH  - Evidence-Based Medicine
MH  - Glucagon-Like Peptide 1/administration & dosage/adverse effects/*analogs & 
      derivatives/pharmacokinetics/therapeutic use
MH  - Glycated Hemoglobin/metabolism
MH  - Humans
MH  - Hypoglycemic Agents/administration & dosage/adverse 
      effects/pharmacokinetics/*therapeutic use
MH  - Liraglutide
MH  - Treatment Outcome
EDAT- 2011/05/14 06:00
MHDA- 2011/10/01 06:00
CRDT- 2011/05/14 06:00
PHST- 2011/05/14 06:00 [entrez]
PHST- 2011/05/14 06:00 [pubmed]
PHST- 2011/10/01 06:00 [medline]
AID - 10.1517/14712598.2011.583641 [doi]
PST - ppublish
SO  - Expert Opin Biol Ther. 2011 Jul;11(7):951-9. doi: 10.1517/14712598.2011.583641. 
      Epub 2011 May 12.